Veracyte Inc (OQ:VCYT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 6000 Shoreline Court, Suite 300
Tel: N/A
IR: See website
Key People
Marc A. Stapley
Chief Executive Officer, Director
Rebecca Chambers
Chief Financial Officer
Annie Mcguire
Chief People Officer, Executive Vice President
Phillip G. Febbo
Chief Scientific Officer, Chief Medical Officer
Business Overview
Veracyte, Inc. is a global diagnostics company. The Company is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. It offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. It also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. It also offers customized biomarker testing and analytical services.
Financial Overview
For the nine months ended 30 September 2023, Veracyte Inc revenues increased 22% to $262.9M. Net loss increased 41% to $46.1M. Revenues reflect Development and commercialization segment increase from $72.9M to $180.4M. Higher net loss reflects Development and commercialization segment loss increase from $10.7M to $39.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.46 to -$0.63.
Employees: 787 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $1,625M as of Sep 30, 2023
Annual revenue (TTM): $343.15M as of Sep 30, 2023
EBITDA (TTM): $8.00M as of Sep 30, 2023
Net annual income (TTM): -$49.96M as of Sep 30, 2023
Free cash flow (TTM): $29.08M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 73,039,671 as of Nov 3, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.